CONTEXT THERAPEUTICS INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
CONTEXT THERAPEUTICS INC. (CNTX) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $6.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-05
- 2026-06-30: Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month $6.50M.
- 2025-06-30: Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month $0.00.
- 2024-09-30: Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month $14.75M.
- 2023-09-30: Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month |
|---|---|---|
| 2026-06-30 | $6.50M 10-Q · filed 2026-08-05 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $14.75M 10-Q · filed 2024-11-06 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |